Exploring using HBsAg to predict interferon treatment course to achieve clinical cure in chronic hepatitis B patients: a clinical study
Baseline HBsAg in chronic hepatitis B patients were a risk factor for prolonged IFN treatment course with a positive correlation. Ultimately, a personalized model based on baseline HBsAg levels can be established to roughly estimate the duration of interferon therapy prior to treatment initiation, thereby guiding clinical decision-making.
Authors
- Qin Du
- Baiguo Xu (ORCID: https://orcid.org/0000-0002-0269-5155)
- Fei Yan (ORCID: https://orcid.org/0000-0003-4874-9582)
- Fei Tang (ORCID: https://orcid.org/0000-0003-1475-5028)
- Jing Chen (ORCID: https://orcid.org/0000-0002-3145-8220)
- Qing Ye (ORCID: https://orcid.org/0009-0004-5439-1892)
- Fang Wang (ORCID: https://orcid.org/0000-0002-9715-1838)
- Lei Liu (ORCID: https://orcid.org/0000-0001-6290-8602)
- Jing Liang (ORCID: https://orcid.org/0000-0003-0811-0223)
- Yicheng Lin
- Huiling Xiang (ORCID: https://orcid.org/0000-0001-5734-4080)
- Weili Yin
- Xinyu Chen (ORCID: https://orcid.org/0009-0008-6347-2490)
Institutions
- Nankai University (CN)
- Tianjin Third Central Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3389/fimmu.2024.1528758
- Citations
- 3
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.06